Evidence map›Paper›PMID 41790220›Full record

ReviewDie Ophthalmologie2026

[Remodeling of the internal retina-Implications for targeted optogenetics].

Feros Bator, Shreshth Shekhar, Hans Hoerauf, Tim Gollisch, Christian van Oterendorp, Moritz Lindner

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Die Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Feros BatorKlinik für Augenheilkunde, Universitätsmedizin Göttingen, Göttingen, Deutschland.
Shreshth ShekharKlinik für Augenheilkunde, Universitätsmedizin Göttingen, Göttingen, Deutschland.
Hans HoeraufKlinik für Augenheilkunde, Universitätsmedizin Göttingen, Göttingen, Deutschland.
Tim GollischKlinik für Augenheilkunde, Universitätsmedizin Göttingen, Göttingen, Deutschland.ORCID http://orcid.org/0000-0003-3998-533X
Christian van OterendorpKlinik für Augenheilkunde, Universitätsmedizin Göttingen, Göttingen, Deutschland. christian.oterendorp@med.uni-goettingen.de.ORCID http://orcid.org/0009-0000-3237-3803
Moritz LindnerInstitut für Physiologie und Pathophysiologie, Philipps-Universität Marburg, Marburg, Deutschland. moritz.lindner@uni-marburg.de.ORCID http://orcid.org/0000-0002-4416-3421

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor the design of optogenetic treatment approaches for degenerative retinal disorders two factors are of key relevance: firstly, the treatment targets a diseased retina where morphology and function may already be severely altered. These alterations are referred to as remodeling. The second factor is the complex signal processing in the retina, which may be altered by this remodeling or short-circuited by optogenetic therapy. RESEARCH QUESTION: This article presents the current state of knowledge on disease-related morphological and functional remodeling processes in the retina and discusses the challenges for optogenetic treatment approaches. MATERIAL AND

methodsThe article presents a narrative review.

resultsAlthough hereditary diseases, such as retinitis pigmentosa primarily affect the outer retina, the structural and functional remodeling processes eventually affect all retinal layers. The current understanding of this process is largely based on animal studies. State-of-the-art, high-resolution imaging methods could help to gain a better understanding of remodeling in human patients and could enable identification of the optimal target cell population for optogenetic treatment approaches in patients with advanced retinal degeneration, depending on the stage of the disease.

conclusionRemodeling processes and retinal signal processing must be taken into account when designing optogenetic treatment approaches. In the long term the goal must be to develop targeted approaches for both ganglion cells and bipolar cells in order to make optimal use of the remaining functions depending on the stage of the disease.

Indexed as

OptogeneticsRetinaRetinal DegenerationAnimalsHumansRetinal Ganglion CellsBipolar cellsGanglion cellsGene therapyOptogenetic restoration of visionSignal processing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.